Utility of Contrast-Enhanced T2 FLAIR for Imaging Brain Metastases Using a Half-dose High-Relaxivity Contrast Agent.

Area of Science:

• Radiology
• Medical Imaging
• Oncology

Background:

• Efficient detection of brain metastases is crucial for effective patient treatment.
• Contrast-enhanced magnetic resonance imaging (MRI) plays a vital role in identifying metastatic lesions in the brain.

Purpose of the Study:

• To evaluate the clinical utility of contrast-enhanced T2 FLAIR imaging using a reduced dose of gadobenate dimeglumine for detecting brain metastases.
• To compare the enhancement characteristics of different types of brain metastases using this imaging technique.

Main Methods:

• In vitro analysis of signal intensity with varying gadolinium concentrations on T1-weighted imaging (T1WI) and T2 FLAIR.
• Prospective study involving 46 lung cancer patients undergoing nonenhanced T2 FLAIR, followed by contrast-enhanced T2 FLAIR and T1WI after half-dose gadobenate dimeglumine administration.
• Classification of brain metastases into solid-enhancing (Group A), ring-enhancing (Group B), and small lesions (<5 mm, Group C) for comparative analysis.

Main Results:

• In vitro, T2 FLAIR achieved maximal signal intensity at lower gadolinium concentrations compared to T1WI.
• In vivo, contrast-enhanced T2 FLAIR demonstrated mean contrast ratios for metastases ranging from 63.64% to 83.05%.
• The percentage increase in enhancement on contrast-enhanced T2 FLAIR was significantly lower for solid-enhancing metastases (Group A) compared to ring-enhancing (Group B) and small lesions (Group C).

Conclusions:

• Delayed contrast-enhanced T2 FLAIR with a half-dose of a high-relaxivity contrast agent enhances the visualization of small or ring-enhancing brain metastases.
• This optimized imaging protocol offers improved detection capabilities for specific types of brain metastases, potentially impacting treatment strategies.